









市場行情
/
股票
/
nasdaq-mdwd
/

Mediwound Ltd

MDWD

18.620USD

-0.150-0.80%

收盤 12/22, 16:00（美東）報價延遲15分鐘

238.74M總市值

虧損本益比TTM



Mediwound Ltd

18.620

-0.150-0.80%

概覽公司財務分析

概覽

公司

財務

分析

關於 Mediwound Ltd 公司

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Mediwound Ltd簡介



公司代碼MDWD

公司名稱Mediwound Ltd

上市日期Mar 20, 2014

CEOGonen (Ofer)

員工數量111

證券類型Ordinary Share

年結日Mar 20

公司地址42 Hayarkon Street

城市YAVNE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Israel

郵編8122745

電話972779714100

網址https://www.mediwound.com/

公司代碼MDWD

上市日期Mar 20, 2014

CEOGonen (Ofer)

Mediwound Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Ofer Gonen

Chief Executive Officer, Director

182.10K

+84.44%

Mr. Nachum (Homi) Shamir

Independent Chairman of the Board

Mr. Jeremy Feffer

Managing Director

Ms. Hani Luxenburg

Chief Financial Officer

Mr. Stephen T. Wills, CPA

Independent Director

Dr. Ety Klinger, Ph.D.

Chief Research and Development Officer

Dr. Shmulik Hess

Chief Operating Officer, Chief Commercial Officer

Dr. Robert J. Snyder

Chief Medical Officer

Mr. David Fox

Independent Director

Dr. Vickie R. Driver, M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Ofer Gonen

Chief Executive Officer, Director

182.10K

+84.44%

Mr. Nachum (Homi) Shamir

Independent Chairman of the Board

Mr. Jeremy Feffer

Managing Director

Ms. Hani Luxenburg

Chief Financial Officer

Mr. Stephen T. Wills, CPA

Independent Director

Dr. Ety Klinger, Ph.D.

Chief Research and Development Officer

收入明細

單位: USD更新時間: 10月6日週一

FY2024

FY2023

FY2022

FY2021

FY2020

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

USA

15.46M

76.47%

EU and other international markets

4.76M

23.53%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月5日週五

持股股東

股東類型

持股股東

佔比

Clal Biotechnology Industries Ltd

11.55%

Investor AB

6.80%

Yelin Lapidot Provident Funds Management Ltd

6.32%

Rosalind Advisors, Inc.

5.84%

HOLD Alapkezelo Zrt

5.49%

其他

64.00%

持股股東

佔比

Clal Biotechnology Industries Ltd

11.55%

Investor AB

6.80%

Yelin Lapidot Provident Funds Management Ltd

6.32%

Rosalind Advisors, Inc.

5.84%

HOLD Alapkezelo Zrt

5.49%

其他

64.00%

股東類型

持股股東

佔比

Investment Advisor

22.91%

Holding Company

11.55%

Hedge Fund

10.81%

Investment Advisor/Hedge Fund

8.44%

Private Equity

6.80%

Venture Capital

2.95%

Corporation

2.17%

Individual Investor

1.42%

Research Firm

0.83%

其他

32.12%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

135

5.72M

44.57%

+391.20K

2025Q2

127

6.70M

61.97%

-1.10M

2025Q1

129

6.76M

62.72%

-1.01M

2024Q4

118

7.26M

67.33%

+161.02K

2024Q3

115

7.34M

70.49%

+440.76K

2024Q2

5.75M

66.40%

+288.97K

2024Q1

5.35M

61.63%

-376.56K

2023Q4

5.55M

64.63%

+32.10K

2023Q3

5.26M

71.22%

+1.01M

2023Q2

5.23M

72.67%

+954.42K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Clal Biotechnology Industries Ltd

1.48M

11.55%

Sep 30, 2025

Investor AB

872.09K

6.8%

Jun 30, 2025

Yelin Lapidot Provident Funds Management Ltd

816.74K

6.37%

-41.26K

-4.81%

Jun 30, 2025

Rosalind Advisors, Inc.

407.06K

3.17%

-99.83K

-19.69%

Jun 30, 2025

HOLD Alapkezelo Zrt

703.43K

5.49%

+703.43K

Sep 22, 2025

T. Rowe Price Associates, Inc.

369.08K

2.88%

+214.12K

+138.19%

Jun 30, 2025

Israel Biotech Fund

378.62K

2.95%

-172.63K

-31.32%

Mar 15, 2025

BlackRock Institutional Trust Company, N.A.

388.27K

3.03%

-45.72K

-10.54%

Jun 30, 2025

Deep Insight Limited Partnership

278.18K

2.17%

-273.07K

-49.54%

Mar 15, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

ARK Israel Innovative Technology ETF

1.64%

Invesco NASDAQ Future Gen 200 ETF

0.59%

iShares Micro-Cap ETF

0.03%

iShares Russell 2000 Growth ETF

0.01%

Global X Russell 2000 ETF

0.01%

ProShares Hedge Replication ETF

0.01%

iShares Russell 2000 ETF

Proshares Ultra Russell 2000

ProShares UltraPro Russell2000

ARK Israel Innovative Technology ETF

佔比1.64%

Invesco NASDAQ Future Gen 200 ETF

佔比0.59%

iShares Micro-Cap ETF

佔比0.03%

iShares Russell 2000 Growth ETF

佔比0.01%

Global X Russell 2000 ETF

佔比0.01%

ProShares Hedge Replication ETF

佔比0.01%

iShares Russell 2000 ETF

佔比0%

Proshares Ultra Russell 2000

佔比0%

ProShares UltraPro Russell2000

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

公告日期

類型

比率

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

常見問題

Mediwound Ltd的前五大股東是誰？



Mediwound Ltd的前五大股東如下：
Clal Biotechnology Industries Ltd
持有股份：1.48M
佔總股份比例：11.55%。
Investor AB
持有股份：872.09K
佔總股份比例：6.80%。
Yelin Lapidot Provident Funds Management Ltd
持有股份：816.74K
佔總股份比例：6.37%。
Rosalind Advisors, Inc.
持有股份：407.06K
佔總股份比例：3.17%。
HOLD Alapkezelo Zrt
持有股份：703.43K
佔總股份比例：5.49%。